CTC Clinical Trial Consultants AB

At CTC Clinical Trial Consultants AB, investigators are evaluating vaccines and treatments aimed at preventing serious bacterial and fungal infections.

• Pneumococcal disease vaccine V116 safety and immunogenicity in children
• Assessment of serotype‑specific opsonophagocytic activity
• Exploration of novel antimicrobial strategies

The trials seek to improve protection against pneumococcal infection and reduce disease burden in high‑risk populations.

Studies focus on disorders of the gastrointestinal tract, especially celiac disease, to restore intestinal health.

• Evaluation of amlitelimab for non‑responsive celiac disease
• Investigation of gluten‑induced mucosal changes under adjunctive therapy
• Impact of treatment on nutrient absorption and quality of life

The purpose is to test new biologic agents that can reduce intestinal inflammation and improve patient outcomes.

Research targets immune‑mediated conditions such as atopic dermatitis and alopecia areata.

• Amlitelimab monotherapy versus placebo for moderate‑to‑severe atopic dermatitis
• Upadacitinib dosing strategies for severe alopecia areata in adults and adolescents
• Long‑term safety monitoring of immune‑modulating agents

Goals include reducing skin inflammation, promoting hair regrowth, and establishing safe treatment regimens.

Clinical trials explore innovative solutions for erectile dysfunction.

• LIB‑01 efficacy compared with placebo in improving sexual function
• Comprehensive safety assessment of LIB‑01
• Patient‑reported outcome measures of treatment satisfaction

The studies aim to provide a new therapeutic option that enhances performance and quality of life for men.

The site conducts trials on metabolic disorders, focusing on type 2 diabetes.

• CagriSema versus semaglutide on HbA1c reduction
• Evaluation of body‑weight changes alongside glycemic control
• Assessment of safety in combination with metformin ± SGLT2 inhibitor

The objective is to identify more effective glucose‑lowering agents that also support weight management.

Investigations address chronic skin conditions, particularly atopic dermatitis.

• Amlitelimab subcutaneous administration for severe eczema
• Comparison of two dosing regimens and treatment withdrawal effects
• Safety and tolerability profiling over extended periods

The purpose is to expand therapeutic choices for patients who have not responded to existing treatments.

Research examines addictive behaviors, including nicotine dependence.

• Pharmacokinetic comparison of nicotine pouch (NP) dry 4 mg versus Nicorette® lozenge
• Evaluation of craving reduction and user satisfaction
• Safety monitoring in healthy adult cigarette users

The aim is to develop safer nicotine replacement products that support cessation efforts.

Trials focus on major depressive disorder with insomnia symptoms and adjunctive therapies.

• Seltorexant 20 mg added to SSRI/SNRI for acute depressive symptom improvement
• Long‑term efficacy of seltorexant in delaying relapse after stable response
• Safety assessment of combined antidepressant regimen

The objective is to enhance depressive symptom relief and maintain remission in patients with inadequate response to standard antidepressants.